Last reviewed · How we verify
Fecal Microbial transplant Capsules
At a glance
| Generic name | Fecal Microbial transplant Capsules |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fecal Microbial Transplants for the Treatment of Pancreatic Cancer (EARLY_PHASE1)
- Fecal Microbiota Transplantation Intervention on Microbiota Composition and Insulin Sensitivity in Diabetes (NA)
- Aging Resilience Through Microbiota Optimization and Regulation (PHASE1)
- Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV) (NA)
- Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms (NA)
- Efficacy and Safety of Fecal Microbiota Transfer (FMT) for Recurrent Urinary Tract Infections in Women (PHASE2)
- Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders (NA)
- Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |